Stock comparison
Alvotech
United Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ALVO
Alvotech
Market cap
$1.04B
Sector
Healthcare
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
Overall winner
United Therapeutics UTHR
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ALVO | UTHR | Winner |
|---|---|---|---|
| Warren Buffett | 44D | 71B | UTHR |
| Benjamin Graham | 51D | 76B | UTHR |
| Philip Fisher | 55C | 76B | UTHR |
| Peter Lynch | 78C | 62C | ALVO |
| Joel Greenblatt | 45D | 46D | UTHR |
| Charlie Munger | 52D | 64C | UTHR |
| Terry Smith | 43D | 64C | UTHR |
Side-by-side metrics
| Metric | ALVO | UTHR |
|---|---|---|
| Market cap | $1.04B | $24.13B |
| P/E (TTM) | 33.1x | 19.2x |
| EV/EBIT | 29.5x | 15.2x |
| ROIC (TTM) | 1.3% | 18.81% |
| Gross margin | 59.82% | 86.58% |
| Net margin | 4.76% | 40.61% |
| Revenue CAGR 5y | 99.83% | 17.22% |
| EPS CAGR 5y | - | 29.84% |
| Debt / Equity | - | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ALVO leads on
- Debt / Equity-vs -+100%
- Revenue CAGR 5y99.83%vs 17.22%+83%
UTHR leads on
- Market cap$24.13Bvs $1.04B+96%
- ROIC (TTM)18.81%vs 1.3%+93%
- Net margin40.61%vs 4.76%+88%
- EV/EBIT15.2xvs 29.5x+49%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.